一名转移性乳腺癌患者使用哌柏西利后出现类史蒂文斯-约翰逊综合征皮疹。 - Suppr

Suppr

超能文献

Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer.

作者信息

Karagounis Theodora, Vallurupalli Mounica, Nathan Neera, Nazarian Rosalynn, Vedak Priyanka, Spring Laura, Chen Steven T

机构信息

College of Physicians and Surgeons, Columbia University Medical Center, New York, New York.

Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.

出版信息

JAAD Case Rep. 2018 Apr 30;4(5):452-454. doi: 10.1016/j.jdcr.2017.12.015. eCollection 2018 Jun.

DOI:10.1016/j.jdcr.2017.12.015

PMID:29984280

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6031570/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1577/6031570/814a13219777/gr1.jpg

相似文献

Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer.

JAAD Case Rep. 2018 Apr 30;4(5):452-454. doi: 10.1016/j.jdcr.2017.12.015. eCollection 2018 Jun.

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.

JAAD Case Rep. 2018 Oct 10;4(9):930-933. doi: 10.1016/j.jdcr.2018.08.003. eCollection 2018 Oct.

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.

Drug Saf. 2019 Jan;42(1):55-66. doi: 10.1007/s40264-018-0711-x.

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.

Adv Ther. 2017 Jun;34(6):1235-1244. doi: 10.1007/s12325-017-0530-y. Epub 2017 Apr 24.

Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.

Drug Saf. 2005;28(10):917-24. doi: 10.2165/00002018-200528100-00008.

Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.

J Am Acad Dermatol. 2014 Mar;70(3):539-48. doi: 10.1016/j.jaad.2013.11.015. Epub 2014 Jan 2.

Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.

Tunis Med. 2015 Jul;93(7):413-5.

Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review.

J Am Acad Dermatol. 2019 Sep;81(3):749-757. doi: 10.1016/j.jaad.2019.05.061. Epub 2019 May 29.

Role of nanocrystalline silver dressings in the management of toxic epidermal necrolysis (TEN) and TEN/Stevens-Johnson syndrome overlap.

Australas J Dermatol. 2015 Nov;56(4):298-302. doi: 10.1111/ajd.12254. Epub 2014 Nov 4.

Toll-like receptor 9 polymorphism in patients with erythema multiforme, Stevens Johnson syndrome and Stevens Johnson syndrome/toxic epidermal necrolysis overlap syndrome.

Bratisl Lek Listy. 2011;112(5):260-3.

引用本文的文献

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors.

Acta Derm Venereol. 2025 Jan 14;105:adv42291. doi: 10.2340/actadv.v105.42291.

Case Report of Probable DRESS Syndrome Associated with Ribociclib.

Case Rep Oncol Med. 2023 Nov 23;2023:7904950. doi: 10.1155/2023/7904950. eCollection 2023.

The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases.

Int J Mol Sci. 2023 Aug 31;24(17):13558. doi: 10.3390/ijms241713558.

Ribociclib and palbociclib-induced erythema multiforme: a case report.

Oxf Med Case Reports. 2022 Nov 24;2022(11):omac116. doi: 10.1093/omcr/omac116. eCollection 2022 Nov.

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review.

Clin Cosmet Investig Dermatol. 2022 Jan 5;15:5-10. doi: 10.2147/CCID.S344867. eCollection 2022.

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Front Pharmacol. 2021 Apr 26;12:588063. doi: 10.3389/fphar.2021.588063. eCollection 2021.

Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.

Drug Saf. 2021 Jul;44(7):725-732. doi: 10.1007/s40264-021-01071-1. Epub 2021 May 6.

CDK4/6 inhibitor palbociclib reduces inflammation in lupus-prone mice.

Am J Clin Exp Urol. 2021 Feb 15;9(1):32-43. eCollection 2021.

Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity.

Cureus. 2020 Sep 3;12(9):e10229. doi: 10.7759/cureus.10229.

J Breast Cancer. 2019 Dec;22(4):661-666. doi: 10.4048/jbc.2019.22.e44.

本文引用的文献

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3.

Targeting CDK4 and CDK6: From Discovery to Therapy.

Cancer Discov. 2016 Apr;6(4):353-67. doi: 10.1158/2159-8290.CD-15-0894. Epub 2015 Dec 11.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

Ann Oncol. 2014 Dec;25(12):2357-2362. doi: 10.1093/annonc/mdu456. Epub 2014 Sep 17.

Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.

J Am Acad Dermatol. 2013 Aug;69(2):173.e1-13; quiz 185-6. doi: 10.1016/j.jaad.2013.05.003.

ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Clin Pharmacol Ther. 2010 Jul;88(1):60-8. doi: 10.1038/clpt.2009.252. Epub 2010 Apr 7.

Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.

Arch Dermatol. 1987 Sep;123(9):1160-5. doi: 10.1001/archderm.123.9.1160.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验